JPH05506990A - プロテアーゼ　ネキシン―２の精製、検出、及び使用方法 - Google Patents

プロテアーゼ　ネキシン―２の精製、検出、及び使用方法

Info

Publication number
JPH05506990A
JPH05506990A JP91508302A JP50830291A JPH05506990A JP H05506990 A JPH05506990 A JP H05506990A JP 91508302 A JP91508302 A JP 91508302A JP 50830291 A JP50830291 A JP 50830291A JP H05506990 A JPH05506990 A JP H05506990A
Authority
JP
Japan
Prior art keywords
βapp
disease
alzheimer
protease
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP91508302A
Other languages
English (en)
Japanese (ja)
Inventor
バンノーストランド　ウイリアム　イー．
キューニンガム　デニス　デー．
ワーグナー　スチーブン　エル．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JPH05506990A publication Critical patent/JPH05506990A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Television Signal Processing For Recording (AREA)
  • Closed-Circuit Television Systems (AREA)
  • Alarm Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP91508302A 1990-04-24 1991-03-25 プロテアーゼ　ネキシン―２の精製、検出、及び使用方法 Pending JPH05506990A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51378690A 1990-04-24 1990-04-24
US513,786 1990-04-24
PCT/US1991/001971 WO1991016628A1 (en) 1990-04-24 1991-03-25 Purification, detection and methods of use of protease nexin-2

Publications (1)

Publication Number Publication Date
JPH05506990A true JPH05506990A (ja) 1993-10-14

Family

ID=24044677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP91508302A Pending JPH05506990A (ja) 1990-04-24 1991-03-25 プロテアーゼ　ネキシン―２の精製、検出、及び使用方法

Country Status (5)

Country Link
US (1) US5270165A (enExample)
EP (1) EP0527823A1 (enExample)
JP (1) JPH05506990A (enExample)
CA (1) CA2079880A1 (enExample)
WO (1) WO1991016628A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017053874A (ja) * 2016-12-22 2017-03-16 国立研究開発法人理化学研究所 急性冠症候群のマーカー及びその利用

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
EP0568575B2 (en) 1991-01-21 2010-11-03 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
CA2123211C (en) 1991-11-12 2008-09-16 Colin L. Masters A method for assaying and treating alzheimer's disease
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
EP0701441A1 (en) * 1993-06-01 1996-03-20 Cortex Pharmaceuticals, Inc. Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
JP3356556B2 (ja) * 1993-10-22 2002-12-16 第一化学薬品株式会社 変性リポプロテイン類の測定法
CA2174429C (en) 1993-10-27 2011-08-30 Lisa C. Mcconlogue Transgenic animals harboring app allele having swedish mutation
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US5998149A (en) 1996-04-05 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Method of detecting transmissible spongiform encephalopathies
EP0812569A1 (de) * 1996-06-10 1997-12-17 Arrowdean Ltd. Verfahren zur Bestimmung der Bioverfügbarkeit und/oder Blut-Hirn-Schrankenpermeabilität einer chemischen Verbindung
US5976817A (en) * 1996-10-31 1999-11-02 Trustees Of Boston University Diagnostic method for detecting Alzheimer's disease in living patients
ATE223058T1 (de) * 1997-09-19 2002-09-15 Evotec Ag Verfahren zur messung der assoziation von teilstrukturen pathologischer proteinablagerungen
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
WO1999032659A1 (en) * 1997-12-22 1999-07-01 Stiftelsen Universitetsforskning Bergen (Unifob) METHOD FOR DISEASE PROGNOSIS BASED ON Fc RECEPTOR GENOTYPING
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
RU2159438C2 (ru) * 1999-03-01 2000-11-20 Батыршин Ринат Авхадиевич Способ дифференциальной диагностики геморрагической лихорадки с почечным синдромом у реконвалесцентов с острыми респираторными вирусными инфекциями
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2001016364A2 (en) * 1999-09-01 2001-03-08 Evotec Neurosciences Gmbh Methods of diagnosing or prognosticating age-related macular degeneration
US6773704B1 (en) 1999-10-28 2004-08-10 The Brigham And Women's Hospital, Inc. Methods of treating vascular disease associated with cystatin C deficiency
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
GB0128793D0 (en) * 2001-11-30 2002-01-23 Novartis Forschungsstiftung Screening method for compounds that modulate neuronal activity
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
KR20070040824A (ko) 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP2010514700A (ja) * 2006-12-22 2010-05-06 ジェネンテック， インコーポレイテッド Ｄｒ６アンタゴニスト及び神経障害の治療におけるその使用法
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613920B2 (en) 2007-07-27 2013-12-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
MX2010013628A (es) * 2008-06-12 2010-12-21 Genentech Inc Metodo para seleccionar compuestos que inhiben la neurodegeneracion.
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8501178B2 (en) 2008-11-25 2013-08-06 Biogen Idec Ma Inc. Use of DR6 and p75 antagonists to promote survival of cells of the nervous system
CA2780319A1 (en) * 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
CN104122400B (zh) * 2014-07-01 2016-03-02 上海依科赛生物制品有限公司 一种人体β淀粉样蛋白检测试剂盒及其用途
CN113447660A (zh) * 2021-07-08 2021-09-28 西南医科大学附属中医医院 人脑胶质瘤诊断elisa试剂盒及脑脊液app的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5187153A (en) * 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
CA1340802C (en) * 1987-08-15 1999-10-26 Yasuyuki Takahashi Senile amyloid precursor protein and an antibody specific for the same
US4837164A (en) * 1988-04-27 1989-06-06 Bionix Corporation Methods for diagonosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017053874A (ja) * 2016-12-22 2017-03-16 国立研究開発法人理化学研究所 急性冠症候群のマーカー及びその利用

Also Published As

Publication number Publication date
US5270165A (en) 1993-12-14
EP0527823A1 (en) 1993-02-24
CA2079880A1 (en) 1991-10-25
EP0527823A4 (enExample) 1994-04-06
WO1991016628A1 (en) 1991-10-31

Similar Documents

Publication Publication Date Title
JPH05506990A (ja) プロテアーゼ　ネキシン―２の精製、検出、及び使用方法
Koronyo-Hamaoui et al. Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease
Lee Cortical areas differentially involved in multiplication and subtraction: a functional magnetic resonance imaging study and correlation with a case of selective acalculia
Wiendl et al. Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA‐G
Pingault et al. Peripheral neuropathy with hypomyelination, chronic intestinal pseudo‐obstruction and deafness: A developmental “neural crest syndrome” related to a SOX10 mutation
Borthwick et al. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death
May et al. Functional magnetic resonance imaging in spontaneous attacks of SUNCT: Short‐lasting neuralgiform headache with conjunctival injection and tearing
Nygaard et al. Localization of a gene for myoclonus‐dystonia to chromosome 7q21‐q31
Houdart et al. Aneurysm of a dural sigmoid sinus: a novel vascular cause of pulsatile tinnitus
Saiz et al. Detection of 14‐3‐3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders
US5200339A (en) Proteases causing abnormal degradation of amyloid β-protein precursor
Planté‐Bordeneuve et al. The Roussy‐Lèvy family: from the original description to the gene
JP2000507828A (ja) アルツハイマー病の診断および治療法
Gardella et al. Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA
Gutmann et al. Developmental regulation of a neuron‐specific neurofibromatosis 1 isoform
US5213962A (en) Purification, detection and methods of use of protease Nexin-2
EP0546084A1 (en) PROTEASES CAUSING ABNORMAL DEGRADATION OF AMYLOID $g(b)-PROTEIN PRECURSOR
Pirttilä et al. Cystatin C expression is associated with granule cell dispersion in epilepsy
Scaravilli et al. Sporadic fatal insomnia: a case study
Rasmussen et al. Subtle brain damage cannot be detected by measuring neuron-specific enolase and S-100β protein after carotid endarterectomy
Stańczykiewicz et al. Cystatins: unravelling the biological implications for neuroprotection
Bernstein et al. Reduced neuronal co-localisation of nardilysin and the putative α-secretases ADAM10 and ADAM17 in Alzheimer’s disease and Down syndrome brains
Salama et al. Increased midkine levels in sera from patients with Alzheimer's disease
Yue et al. Upregulated SHP‐2 expression in the epileptogenic zone of temporal lobe epilepsy and various effects of SHP099 treatment on a pilocarpine model
US5367063A (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis